ReviewCurrent cardiology reports2012
Targeting high density lipoproteins in the prevention of cardiovascular disease?
Review in Current cardiology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- A decreased level of high-density lipoprotein is a possible risk factor for type 2 diabetes mellitus: A review.Health science reports · 2023Article
- CRISPR/dCas9 Transcriptional Activation of Endogenous Apolipoprotein AI and Paraoxonase 1 in Enterocytes Alleviates Endothelial Cell Dysfunction.Biomolecules · 2021Article
- AIBP protects against metabolic abnormalities and atherosclerosis.Journal of lipid research · 2018Article
- Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients.Scientific reports · 2017Article
- Salicylate improves macrophage cholesterol homeostasis via activation of Ampk.Journal of lipid research · 2015Article
- Article
- The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha.Cell metabolism · 2014Article
- HDL-targeted therapies: progress, failures and future.Nature reviews. Drug discovery · 2014Review
- Liver-specific transgenic expression of cholesteryl ester hydrolase reduces atherosclerosis in Ldlr-/- mice.Journal of lipid research · 2014Article
- An in-silico model of lipoprotein metabolism and kinetics for the evaluation of targets and biomarkers in the reverse cholesterol transport pathway.PLoS computational biology · 2014Article
- Clinical and biological relevance of statin-mediated changes in HDL metabolism.Current atherosclerosis reports · 2014Review
- Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Clinical lipidology · 2013Article
- High-density lipoprotein maintains skeletal muscle function by modulating cellular respiration in mice.Circulation · 2013Article
- Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond.Journal of lipid research · 2013Review
- Genetics of lipid traits and relationship to coronary artery disease.Current cardiology reports · 2013Review
- Liver-specific cholesteryl ester hydrolase deficiency attenuates sterol elimination in the feces and increases atherosclerosis in ldlr-/- mice.Arteriosclerosis, thrombosis, and vascular biology · 2013Article
- Nuclear receptors and microRNA-144 coordinately regulate cholesterol efflux.Circulation research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Recent studies involving HDL-raising therapeutics have greatly changed our understanding of this field. Despite effectively raising HDL-C levels, niacin remains of uncertain clinical benefit. Synthetic niacin receptor agonists are unlikely to raise HDL-C or have other beneficial effects on plasma lipids. Despite the failure in phase 3 of 2 CETP inhibitors, 2 potent CETP inhibitors that raise HDL-C levels by >100 % (and reduce LDL-C substantially) are in late stage clinical development. Infusions of recombinant HDL containing 'wild-type' apoA-I or apoA-I Milano, as well as autologous delipidated HDL, all demonstrated promising early results, and remain in clinical development. A small molecule that causes upregulation of endogenous apoA-I production is also in clinical development. Finally, upregulation of macrophage cholesterol efflux pathways through agonism of liver X receptors or antagonism of miR-33 remains of substantial interest. The field of HDL therapeutics is poised to transition from the 'HDL-cholesterol hypothesis' to the 'HDL flux hypothesis' in which the impact on flux from macrophage to feces is deemed to be of greater therapeutic benefit than the increase in steady-state concentrations of HDL cholesterol.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.